Therapeutic response to pregabalin in neuropathic pain remain unaffected by the use of other pain medications

Primary tabs

NEWS
Therapeutic response to pregabalin in neuropathic pain remain unaffected by the use of other pain medications

Combination therapy with multiple agents is frequently received by the neuropathic pain (NP) patients for ameliorating both pain and any accompanying comorbidities. Pregabalin is often advised as a first-line treatment of NP and few studies have also examined the effects of concomitant medications on the efficacy of pregabalin.

Schug S A,  et. Al., conducted a pooled retrospective data analyses from randomized clinical trials to investigate the effects of concomitant medications on the efficacy and safety of pregabalin in the treatment of NP.

 The data was obtained from 7 randomized placebo-controlled trials of pregabalin (150, 300, 600, and flexible 150 - 600 mg/d) for the treatment of postherpetic neuralgia (PHN) and 2 randomized placebo-controlled trials for the treatment of NP, due to spinal cord injury (SCI-NP). Every day, the patients evaluated the severity of their pain and pain-related sleep interference (PRSI) over the previous 24 hours on a scale from 0 to 10, higher scores depicted greater severity and also kept track of the occurrence of adverse events.

The changes from baseline in mean weekly pain and PRSI scores were differentiated between patients who received concomitant NP medications and patients who did not receive concomitant NP medications. The outcomes of these comparisons were furnished separately for the PHN (through 4, 8, and 12 weeks) and SCI-NP (through 12 weeks). For each treatment group, common adverse events were also considered.

At most dose levels and time points investigated, pregabalin notably improved both pain and PRSI scores relative to placebo.A little difference was depicted in the extent of therapeutic response to pregabalin between patients who received concomitant NP medications and patients who did not receive concomitant NP medications. Also, the profile of treatment-emergent adverse events appeared to be greatly unaffected by the use of concomitant NP medications in the pooled patient population.

This analysis was restricted to the original trials of pregabalin and could not examine the effects of concomitant NP medications. It was thus culminated that the therapeutic response to pregabalin and the occurrence of adverse events in patients with NP are unaffected by the concurrent use of other NP medications.

Source:

Pain Physician

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/28072797

The original title of the article:

Effect of Concomitant Pain Medications on Response to Pregabalin in Patients with Postherpetic Neuralgia or Spinal Cord InjuryRelated Neuropathic Pain

Authors

Schug SA  et al.

SearchTags: 
Therapeutic, Pregabalin, Neuropathic pain, Nerves, Alpha-2 delta ligand, Pooled retrospective data analyses, Efficacy, Pain scores, PRSI scores
Log in or register to post comments